培菲康联合美沙拉嗪与康复新液对溃疡性结肠炎患者炎症因子及不良反应的影响

Effects of Bifico combined with mesalazine and Kangfuxin Solution on inflammatory factors and adverse reactions in patients with ulcerative colitis

目的探讨双歧杆菌三联活菌胶囊(商品名:培菲康)联合美沙拉嗪与康复新液对溃疡性结肠炎(UC)患者炎症因子及不良反应的影响。方法76例溃疡性结肠炎患者,以入院先后顺序分为对照组及观察组,每组38例。对照组以美沙拉嗪联合康复新液治疗,观察组在对照组基础上加入培菲康治疗。对比两组临床疗效、临床症状(大病次数、便血、腹泻、腹痛)评分、炎症因子[白细胞介素-8(IL-8)、肿瘤坏死因子-α(TNF-α)、超敏C反应蛋白(hs-CRP)]水平及不良反应发生情况。结果观察组总有效率为92.11%,较对照组的73.68%更高,差异显著(P<0.05)。治疗后,观察组大便次数评分(0.75±0.23)分、便血评分(0.58±0.17)分、腹泻评分(0.53±0.16)分、腹痛评分(0.59±0.15)分均较对照组的(1.21±0.38)、(0.84±0.21)、(0.82±0.21)、(0.86±0.19)分更低,差异显著(P<0.05)。治疗后,观察组IL-8(140.64±32.83)μg/L、hs-CRP(3.06±0.86)mg/L、TNF-α(37.17±9.22)ng/L均较对照组的(172.14±39.14)μg/L、(4.45±0.94)mg/L、(48.55±9.53)ng/L更低,差异显著(P<0.05)。观察组不良反应发生率5.26%较对照组的21.05%更低,差异显著(P<0.05)。结论培菲康联合美沙拉嗪与康复新液治疗溃疡性结肠炎疗效确切,临床症状和体内炎症因子水平均可得到有效改善,且安全性较高。

Objective To explore the effects of live combined bifidobacterium,lactobacillus and enterococcus capsules(trade name:Bifico)combined with mesalazine and Kangfuxin Solution on inflammatory factors and adverse reactions in patients with ulcerative colitis.Methods 76 patients with ulcerative colitis were divided into a control group and an observation group according to the order of admission,with 38 cases in each group.The control group was treated with mesalazine combined with Kangfuxin Solution,and the observation group was treated with Bifico on the basis of the control group.Both groups were compared in terms of clinical efficacy,clinical symptoms(stool frequency,blood in stool,diarrhea,abdominal pain)score,levels of inflammatory factors[interleukin-8(IL-8),tumor necrosis factor-α(TNF-α),hypersensitive C-reactive protein(hs-CRP)]and occurrence of adverse reactions.Results The total effective rate of the observation group was 92.11%,which was higher than 73.68%of the control group,and the difference was significant(P<0.05).After treatment,in the observation group,the stool frequency score was(0.75±0.23)points,the blood in stool score was(0.58±0.17)points,the diarrhea score was(0.53±0.16)points and the abdominal pain score was(0.59±0.15)points,which were all lower than(1.21±0.38),(0.84±0.21),(0.82±0.21)and(0.86±0.19)points in the control group,and the difference was significant(P<0.05).After treatment,the observation group had IL-8 of(140.64±32.83)μg/L,hs-CRP of(3.06±0.86)mg/L,and TNF-αof(37.17±9.22)ng/L,which were lower than(172.14±39.14)μg/L,(4.45±0.94)mg/L,and(48.55±9.53)ng/L in the control group,and the difference was significant(P<0.05).The incidence of adverse reactions of 5.26%in the observation group was significantly lower than 21.05%in the control group,and the difference was significant(P<0.05).Conclusion Bifico combined with mesalazine and Kangfuxin solution has a definite effect in the treatment of ulcerative colitis,and the clinical symptoms and the levels of inflammatory factors can be effectively improved,and the safety is high.